Business Context and Reporting Period
Company: Eli Lilly & Co.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2007
Business Overview: Eli Lilly operates primarily in pharmaceutical products, with a non-material animal health segment. The quarter was defined by the acquisition of ICOS Corporation (bringing full ownership of Cialis) and significant legal settlements regarding Zyprexa product liability.
Key Financial Metrics
| Metric | Q1 2007 | Q1 2006 |
|---|---|---|
| Net Sales | $4,226.1 million | $3,714.7 million |
| Net Income | $508.7 million | $834.8 million |
| Earnings Per Share (Diluted) | $0.47 | $0.77 |
| Gross Margin | 78.2% | 78.3% |
| Operating Cash Flow | $891.8 million | $254.5 million |
| Total Debt | $5.36 billion | $3.72 billion (approx. based on prior period) |
| Cash & Equivalents | $2,491.4 million | $3,109.3 million (Dec 31, 2006) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 14% to $4.23 billion, driven by growth in Cymbalta, Zyprexa, and the inclusion of full Cialis sales following the ICOS acquisition.
- Profit Decline: Net income decreased 39% to $508.7 million. This decline was primarily due to non-recurring charges:
- Acquired In-Process R&D: $328.5 million charge (including $303.5 million for ICOS and $25.0 million for OSI Pharmaceuticals).
- Restructuring & Impairments: $123.0 million charge related to facility closures and a voluntary severance program.
- Debt Increase: Total debt rose to $5.36 billion, an increase of $1.64 billion from the prior year-end, largely due to $2.5 billion in debt issued to finance the ICOS acquisition.
- Product Performance:
- Cymbalta: Sales surged 89% to $441.8 million.
- Cialis: Sales increased significantly with full consolidation of ICOS territories.
- Strattera: Sales declined 8% due to lower demand.
Guidance, Outlook, and Risks
Management Guidance (2007)
- Sales: Expected to grow in the low double digits.
- Earnings Per Share:
- Q2 2007: $0.50 to $0.52.
- Full Year 2007: $2.63 to $2.73.
- Expenses: Operating expenses expected to grow in the low double digits due to ICOS integration and increased marketing for key products.
- Capital Expenditures: Approximately $1.1 billion for the year.
Material Risks and Contingencies
- Zyprexa Litigation:
- Product Liability: Approximately 1,650 claims remain unsettled after settling ~28,500 claims. A $500 million settlement for 18,000 claims was recorded in Q4 2006 and is payable in 2007. Trials are expected to begin in Q2 2007.
- Patent Disputes: Ongoing litigation with generic manufacturers (Reddy, Teva, Barr) regarding Zyprexa, Evista, and Gemzar patents. An unfavorable outcome could materially impact results.
- Government Investigations: Civil investigations by the U.S. Attorney and multiple state attorneys general regarding marketing practices and Medicaid reporting. Potential for fines or penalties exists.
- Acquisition Integration: Risks associated with integrating ICOS and Hypnion (acquired April 2007 for $315 million, with an expected $300 million Q2 2007 R&D charge).
- Regulatory: FDA rejection of Arxxant appeal; ongoing negotiations for Symbyax approval.
Investor Verification Checklist
- Acquisition Charges: Verify the final allocation of purchase price for ICOS and Hypnion, specifically the non-deductible in-process R&D charges impacting EPS.
- Zyprexa Exposure: Monitor the outcome of the remaining ~1,650 product liability claims and the status of insurance carrier disputes regarding coverage.
- Patent Validity: Track rulings on Zyprexa, Evista, and Gemzar patent challenges, as loss of exclusivity would materially affect future revenue.
- Government Investigations: Review updates on the multistate investigation into marketing practices and potential fines.
- Debt Servicing: Assess the impact of the increased debt load ($5.36 billion) on interest expenses and liquidity given the reduction in cash balances.